Science

Saptagir Laboratories inks pact with Jubilant Generics on Remdesivir

Our Bureau Hyderabad | Updated on September 14, 2020 Published on September 14, 2020

Remdesivir is an experimental antiviral drug developed by Gilead Sciences Inc. as a course of treatment for Covid-19

Saptagir Laboratories has entered into an exclusive agreement with Jubilant Generics, a Jubilant Life Sciences company, to manufacture intermediates and active pharmaceutical ingredients (APIs) used for intravenously-administered drug Remdesivir.

The drug will be produced at its World Health Organisation (WHO) Good Manufacturing Practices (GMP)-certified sterile drug product manufacturing plant at Hyderabad, acquired for ₹75 crore.

“This partnership is timely and in line with our strategic growth plans for the company. Our foray into bulk drugs manufacturing will open new revenue streams,” Shilpa Reddy, Promoter and Managing Director, Saptagir Laboratories, said in a release issued on Monday.

Dr Reddy’s launches Remdesivir as Redyx in India

Remdesivir is an experimental antiviral drug developed by Gilead Sciences Inc. as a course of treatment for Covid-19. Gilead entered into a non-exclusive licensing agreement with Jubilant Life Sciences for distribution to 127 countries.

Following this, Jubilant Life Sciences, through its subsidiary Jubilant Generics, entered into an exclusive agreement with Saptagir Laboratories to manufacture Remdesivir.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 14, 2020
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.